Project Grant R01AG097531
- The National Institute on Aging awarded the University of Rochester $227,250 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate macrophage spatial heterogeneity in regulating hematopoietic aging and inflammation-related stem cell dysfunction. The research examines how resident macrophages in different bone marrow microenvironments regulate hematopoietic stem cell (HSC) division symmetry and fitness during aging. Using intravital microscopy and HSC reporter...
- The National Institute on Aging awarded $735,047 to Vanderbilt University Medical Center on August 15, 2026, under the Aging Research program (CFDA 93.866) to conduct a randomized controlled trial testing a perioperative geriatric intervention for older adults undergoing major cancer surgery. The award funds a multicenter hybrid implementation-effectiveness trial enrolling 354 patients at two NCI-designated cancer centers. The intervention, called PERI-OP, consists of a preoperative in-person or...
- The National Institute on Aging awarded the University of Rochester $188,445 on August 5, 2026, under the Aging Research program (CFDA 93.866) to conduct a randomized controlled trial evaluating dyadic life review therapy for distressed caregivers of older patients with Alzheimer's disease and related dementias and advanced cancer. The study will enroll 60 dyads of patients aged 65 and older with clinical impressions of AD/ADRD (including mild cognitive impairment) and stage III or IV cancer,...
- The National Institute on Aging awarded New York University $3.053 million on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct longitudinal research on caregiving networks and their consequences among adults ages 85 and older. The award funds the ARIC CARES study, embedded within the Atherosclerosis Risk in Communities Study cohort. The research will characterize care ecosystems and relational coordination (teamwork) among family caregivers, paid caregivers, and...
- The National Institute on Aging awarded the University of Rochester $656,829 under the Aging Research program (CFDA 93.866) on January 1, 2026, to investigate selective vulnerability of the fronto-insular network in aging and Alzheimer's disease through integrated structural, functional, and molecular analyses in mouse models. The research integrates in vivo two-photon imaging to track dendritic spine dynamics and dopaminergic terminal remodeling, fiber photometry to measure neural activity...
- The National Institute on Aging awarded the University of Rochester $588,232 on July 1, 2026, under the Aging Research program (CFDA 93.866, assistance type: Project Grant T32AG092335) to establish a postdoctoral training fellowship supporting up to five trainees over two to three years in pragmatic biopsychosocial research focused on improving health and wellbeing of older adults with serious illness and their family caregivers, including Alzheimer's disease and related dementias. The...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded Weill Medical College of Cornell University $720,523 on June 15, 2026, under the Aging Research program (CFDA 93.866) to evaluate the impact of integrated dual-eligible special needs plans (D-SNPs) on utilization, quality, mortality, and chronic disease management among low-income individuals dually eligible for Medicare and Medicaid who qualify for Medicare based on disability. The study addresses a...
- Federal Grant Award Summary The National Institute on Aging (NIA) awarded a Project Grant of $393,750 to the University of California, Los Angeles (UCLA) on September 22, 2025, under the Aging Research program (CFDA 93.866) to conduct a prospective cohort study investigating how aggressive cancer treatments affect physical function in older adults with gastroesophageal cancer (GEC). The research will enroll patients aged 60 years and older who are initiating systemic treatment (chemotherapy,...
- The National Institute on Aging awarded Fred Hutchinson Cancer Center $1.561 million on April 15, 2026, under the Aging Research program (CFDA 93.866) to investigate immune aging phenotypes in adult survivors of childhood hematologic malignancies and their association with chronic health conditions including congestive heart failure, coronary artery disease, and frailty. The research applies high-dimensional immunological approaches to characterize distinct aging-associated immune cell...
- The National Institute on Aging awarded Albany Medical College $246,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate inter-organelle dynamics during aging in eukaryotic cells. The work will characterize spatial contexts of inter-organelle communication using C. elegans as a model system to identify organellar signatures that develop during aging and proteostasis decline, establishing a platform to understand how aging impacts organelle interactions and...
The National Institute on Aging awarded the University of Rochester $635,825 under the Aging Research program (CFDA 93.866) on September 15, 2026, to evaluate the effects of a geriatric assessment oncology care model in older adults with advanced cancer by leveraging data linkages. The research links data from two major trials evaluating geriatric assessment in oncology care (NCT02107443, NCT02054741) with Centers for Medicare and Medicaid Services utilization and cost data to assess healthcare outcomes and economic impact. The geriatric assessment model identifies aging-related health impairments such as comorbidities and cognitive decline that increase cancer treatment toxicity risk, enabling oncology teams to implement targeted interventions. Previous work demonstrated the model reduces treatment toxicity and improves patient-clinician communication, often resulting in less intensive treatments without compromising survival and potentially reducing reactive healthcare utilization such as unplanned hospitalizations. This analysis seeks to clarify the impact of geriatric assessment on healthcare utilization and economic outcomes across the U.S. healthcare system. Performance occurs at Rochester, New York. The period of performance runs through May 31, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $635.8k | 9/3/26 |